KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income towards Parent Company: 2017-2025

Historic Income towards Parent Company for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Income towards Parent Company rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 139.30%. This contributed to the annual value of -$73.9 million for FY2024, which is 51.55% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Income towards Parent Company of $18.1 million as of Q3 2025, which was down 49.08% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Income towards Parent Company registered a high of $35.6 million during Q2 2025, and its lowest value of -$240.1 million during Q2 2022.
  • For the 3-year period, Amneal Pharmaceuticals' Income towards Parent Company averaged around -$4.0 million, with its median value being $16.8 million (2024).
  • Over the last 5 years, Amneal Pharmaceuticals' Income towards Parent Company had its largest YoY gain of 1,135.41% in 2023, and its largest YoY loss of 1,495.08% in 2023.
  • Amneal Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$20.4 million in 2021, then soared by 71.33% to -$5.9 million in 2022, then slumped by 1,495.08% to -$93.4 million in 2023, then skyrocketed by 77.75% to -$20.8 million in 2024, then surged by 54.22% to $18.1 million in 2025.
  • Its Income towards Parent Company was $18.1 million in Q3 2025, compared to $35.6 million in Q2 2025 and $24.6 million in Q1 2025.